Aker BioMarine Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Aker BioMarineDie Umsatzerlöse des Unternehmens werden voraussichtlich um 6.4% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 100.7% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 100% pro Jahr wachsen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.4% betragen.

Wichtige Informationen

100.7%

Wachstumsrate der Gewinne

100.0%

EPS-Wachstumsrate

Food Gewinnwachstum	29.6%
Wachstumsrate der Einnahmen	-6.4%
Zukünftige Eigenkapitalrendite	8.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

Nov 05

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

Jul 19

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Jul 16

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Jul 11

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

Jun 03

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

Feb 15

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Nov 06

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Sep 06

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Nov 04

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Apr 13

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 18

Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven

Jan 07

Gewinn- und Umsatzwachstumsprognosen

OB:AKBM - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	273	20	23	33	2
12/31/2025	243	10	9	13	2
12/31/2024	257	1	-18	-3	2
9/30/2024	335	3	14	52	N/A
6/30/2024	338	-11	26	69	N/A
3/31/2024	336	-8	6	51	N/A
12/31/2023	335	-9	-2	47	N/A
9/30/2023	227	-15	-20	25	N/A
6/30/2023	242	0	-41	5	N/A
3/31/2023	268	14	-35	12	N/A
12/31/2022	277	10	-31	15	N/A
9/30/2022	274	1	-43	-2	N/A
6/30/2022	268	10	-27	9	N/A
3/31/2022	269	-8	-29	4	N/A
12/31/2021	262	-8	-78	3	N/A
9/30/2021	262	3	-85	-17	N/A
6/30/2021	270	-8	-139	-63	N/A
3/31/2021	268	-14	-134	-59	N/A
12/31/2020	289	-5	-75	-51	N/A
9/30/2020	285	-26	-65	-23	N/A
6/30/2020	284	-28	-12	19	N/A
3/31/2020	278	-18	-3	33	N/A
12/31/2019	246	-24	-115	12	N/A
12/31/2018	154	-1	-57	8	N/A
12/31/2017	126	-18	N/A	N/A	N/A
9/30/2017	123	-15	N/A	N/A	N/A
6/30/2017	122	-11	N/A	N/A	N/A
3/31/2017	119	-5	N/A	N/A	N/A
12/31/2016	117	-2	N/A	21	N/A
9/30/2016	111	-8	N/A	N/A	N/A
6/30/2016	110	0	N/A	N/A	N/A
3/31/2016	109	-3	N/A	N/A	N/A
12/31/2015	105	1	N/A	18	N/A
9/30/2015	105	-5	N/A	N/A	N/A
6/30/2015	103	-14	N/A	N/A	N/A
3/31/2015	111	-13	N/A	N/A	N/A
12/31/2014	112	-17	N/A	-11	N/A
9/30/2014	99	-34	N/A	N/A	N/A
6/30/2014	109	44	N/A	N/A	N/A
3/31/2014	106	43	N/A	N/A	N/A
12/31/2013	109	47	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AKBMDas prognostizierte Gewinnwachstum (100.7% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: AKBMDie Erträge des Unternehmens (100.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Norwegian (10.2% pro Jahr).

Hohe Wachstumserträge: AKBMEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: AKBMDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-6.4% pro Jahr).

Hohe Wachstumseinnahmen: AKBMDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-6.4% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AKBMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.4%).

Aker BioMarine Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 69%

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Recent updates

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine AS Expects to Pay Extraordinary Dividend

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.20 loss in 1Q 2023)

Consensus EPS estimates fall by 69%

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS to Report Q1, 2024 Results on Apr 25, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Chairman recently bought kr5.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Consensus EPS estimates increase by 57%

Now 20% undervalued

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Consensus EPS estimates increase by 136%

Consensus forecasts updated

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

Now 20% undervalued

Forecast breakeven date moved forward to 2022

Now 22% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Aker Biomarine AS Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman recently bought kr9.4m worth of stock

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Chief Executive Officer recently bought kr3.3m worth of stock

Forecast breakeven pushed back to 2022

Forecast breakeven moved forward to 2021

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 loss in 1Q 2020)

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Aker BioMarine AS Announces Executive Elections

New 90-day low: kr106